Clinical Trial Detail

NCT ID NCT02152943
Title Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

Her2-receptor positive breast cancer

Advanced Solid Tumor

Therapies

Everolimus + Letrozole + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST